Azitra Inc |
10%+ Owner |
Common Stock |
2.64M |
$13.2M |
$5.00 |
Jun 21, 2023 |
Directly held by Bios Fund III QP, LP |
Azitra Inc |
10%+ Owner |
Common Stock |
1.02M |
$5.12M |
$5.00 |
Jun 21, 2023 |
Directly held by Bios Fund II QP, LP |
Azitra Inc |
10%+ Owner |
Common Stock |
799K |
$4M |
$5.00 |
Jun 21, 2023 |
Directly held by Bios Fund I, LP |
COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
2.02M |
$3.94M |
$1.95 |
Jun 7, 2024 |
By Bios Fund III QP, LP |
IN8BIO, INC. |
10%+ Owner |
Common Stock |
3.73M |
$3.84M |
$1.03 |
Oct 4, 2024 |
By Bios Fund III QP, LP |
COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
1.42M |
$2.78M |
$1.95 |
Jun 7, 2024 |
By Bios Memory SPV I, LP |
Lantern Pharma Inc. |
10%+ Owner |
Common Stock |
429K |
$2.72M |
$6.33 |
May 24, 2024 |
By Bios Fund II QP, LP |
Lantern Pharma Inc. |
10%+ Owner |
Common Stock |
372K |
$2.35M |
$6.33 |
May 23, 2024 |
By Bios Fund I, LP |
Azitra Inc |
10%+ Owner |
Common Stock |
468K |
$2.34M |
$5.00 |
Jun 21, 2023 |
Directly held by Bios Fund I QP, LP |
Azitra Inc |
10%+ Owner |
Common Stock |
436K |
$2.18M |
$5.00 |
Jun 21, 2023 |
Directly held by Bios Azitra Co-Invest I, LP |
Azitra Inc |
10%+ Owner |
Common Stock |
427K |
$2.13M |
$5.00 |
Jun 21, 2023 |
Directly held by Bios Fund III NT, LP |
Azitra Inc |
10%+ Owner |
Common Stock |
405K |
$2.02M |
$5.00 |
Jun 21, 2023 |
Directly held by Bios Fund III, LP |
IN8BIO, INC. |
10%+ Owner |
Common Stock |
1.88M |
$1.93M |
$1.03 |
Oct 4, 2024 |
By Bios Fund II QP, LP |
Azitra Inc |
10%+ Owner |
Common Stock |
313K |
$1.57M |
$5.00 |
Jun 21, 2023 |
Directly held by Bios Fund II, LP |
Lantern Pharma Inc. |
10%+ Owner |
Common Stock |
218K |
$1.38M |
$6.33 |
May 23, 2024 |
By Bios Fund I QP, LP |
IN8BIO, INC. |
10%+ Owner |
Common Stock |
997K |
$1.03M |
$1.03 |
Oct 4, 2024 |
By BIOS Incysus Co-Invest I, LP |
COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
500K |
$975K |
$1.95 |
Jun 7, 2024 |
By Bios Clinical Opportunity Fund, LP |
Lantern Pharma Inc. |
10%+ Owner |
Common Stock |
131K |
$832K |
$6.33 |
May 24, 2024 |
By Bios Fund II, LP |
COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
419K |
$817K |
$1.95 |
Jun 7, 2024 |
By Bios Fund I, LP |
COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
385K |
$751K |
$1.95 |
Jun 7, 2024 |
By Bios Memory SPV II, LP |
Azitra Inc |
10%+ Owner |
Common Stock |
137K |
$685K |
$5.00 |
Jun 21, 2023 |
Directly held by Bios Fund II NT, LP |
Azitra Inc |
10%+ Owner |
Common Stock |
136K |
$679K |
$5.00 |
Jun 21, 2023 |
Direct |
COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
327K |
$637K |
$1.95 |
Jun 7, 2024 |
By Bios Fund III NT, LP |
IN8BIO, INC. |
10%+ Owner |
Common Stock |
602K |
$620K |
$1.03 |
Oct 4, 2024 |
By Bios Fund III, NT, LP |
COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
310K |
$604K |
$1.95 |
Jun 7, 2024 |
By Bios Fund III, LP |
IN8BIO, INC. |
10%+ Owner |
Common Stock |
574K |
$592K |
$1.03 |
Oct 4, 2024 |
By Bios Fund II, LP |
IN8BIO, INC. |
10%+ Owner |
Common Stock |
571K |
$588K |
$1.03 |
Oct 4, 2024 |
By Bios Fund III, LP |
COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
256K |
$499K |
$1.95 |
Jun 7, 2024 |
By Bios Fund II QP, LP |
COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
245K |
$478K |
$1.95 |
Jun 7, 2024 |
By Bios Fund I QP, LP |
Lantern Pharma Inc. |
10%+ Owner |
Common Stock |
57.5K |
$364K |
$6.33 |
May 24, 2024 |
By Bios Fund II NT, LP |
IN8BIO, INC. |
10%+ Owner |
Common Stock |
251K |
$259K |
$1.03 |
Oct 4, 2024 |
By Bios Fund II NT, LP |
SWK Holdings Corp |
Director |
Common Stock |
9.87K |
$177K |
$17.95 |
Dec 31, 2021 |
Direct |
Lantern Pharma Inc. |
10%+ Owner |
Common Stock |
26.1K |
$165K |
$6.33 |
May 23, 2024 |
By BP Directors, LP |
COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
78.3K |
$153K |
$1.95 |
Jun 7, 2024 |
By Bios Fund II, LP |
COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
34.2K |
$66.8K |
$1.95 |
Jun 7, 2024 |
By Bios Fund II NT, LP |
Azitra Inc |
10%+ Owner |
Common Stock |
13.1K |
$65.5K |
$5.00 |
Jun 21, 2023 |
Directly held by KF Legacy Trust |
Azitra Inc |
10%+ Owner |
Common Stock |
13.1K |
$65.5K |
$5.00 |
Jun 21, 2023 |
Directly held by MF Legacy Trust |
COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Common Stock |
14.5K |
$28.3K |
$1.95 |
Jun 7, 2024 |
Direct |
IN8BIO, INC. |
10%+ Owner |
Pre-Funded Warrants |
1.28M |
|
|
Oct 4, 2024 |
By Bios Clinical Opportunity Fund, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
980K |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II QP, LP |
IN8BIO, INC. |
10%+ Owner |
Series C Warrant |
709K |
|
|
Oct 4, 2024 |
By Bios Clinical Opportunity Fund, LP |
IN8BIO, INC. |
10%+ Owner |
Series A Warrant |
574K |
|
|
Oct 4, 2024 |
By Bios Clinical Opportunity Fund, LP |
IN8BIO, INC. |
10%+ Owner |
Series B Warrant |
574K |
|
|
Oct 4, 2024 |
By Bios Clinical Opportunity Fund, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
300K |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Common Stock |
131K |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II NT, LP |
IN8BIO, INC. |
10%+ Owner |
Stock Option |
85K |
|
|
Oct 4, 2024 |
Indirect |
IN8BIO, INC. |
10%+ Owner |
Stock Option |
85K |
|
|
Dec 13, 2023 |
Indirect |
TFF Pharmaceuticals, Inc. |
Director |
Stock Options (Right to Buy) |
33.5K |
|
|
Dec 29, 2022 |
To BP Directors for the benefit of Reporting Person |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Stock Options |
31.9K |
|
|
Aug 12, 2024 |
Directly held by BP Directors, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Stock Options |
15K |
|
|
Aug 12, 2024 |
Directly held by Aaron G.L. Fletcher |
Cue Biopharma, Inc. |
Director |
Stock Option (right to buy) |
10K |
|
|
Jan 3, 2023 |
Direct |
COGNITION THERAPEUTICS INC |
Director, 10%+ Owner |
Stock Option (right to buy) |
8.5K |
|
|
Jun 7, 2024 |
Direct |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Convertible Note |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Clinical Opportunity Fund, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series A Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund I, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series A Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund I QP, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-1 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Actuate Co-Invest I, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-1 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-1 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II NT, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-1 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II QP, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-2 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Actuate Co-Invest I, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-2 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-2 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II NT, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-2 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II QP, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-3 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-3 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II NT, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-3 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II QP, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-4 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Actuate Co-Invest II, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-4 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund III, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-4 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund III NT, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series B-4 Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund III QP, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series C Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Actuate Co-Invest III, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series C Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund III, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series C Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund III NT, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Series C Redeemable Convertible Preferred Stock |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund III QP, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Warrant (Right to Buy) |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Warrant (Right to Buy) |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II NT, LP |
ACTUATE THERAPEUTICS, INC. |
Director, 10%+ Owner |
Warrant (Right to Buy) |
0 |
|
|
Aug 14, 2024 |
Directly held by Bios Fund II QP, LP |
Azitra Inc |
10%+ Owner |
Convertible Notes |
0 |
|
|
Jun 21, 2023 |
Directly held by Bios Fund III, LP |
Azitra Inc |
10%+ Owner |
Convertible Notes |
0 |
|
|
Jun 21, 2023 |
Directly held by Bios Fund III NT, LP |
Azitra Inc |
10%+ Owner |
Convertible Notes |
0 |
|
|
Jun 21, 2023 |
Directly held by Bios Fund III QP, LP |
Azitra Inc |
10%+ Owner |
Series A-1 Convertible Preferred Stock |
0 |
|
|
Jun 21, 2023 |
Directly held by Bios Azitra Co-Invest I, LP |
Azitra Inc |
10%+ Owner |
Series A-1 Convertible Preferred Stock |
0 |
|
|
Jun 21, 2023 |
Directly held by Bios Fund II, LP |
Azitra Inc |
10%+ Owner |
Series A-1 Convertible Preferred Stock |
0 |
|
|
Jun 21, 2023 |
Directly held by Bios Fund II NT, LP |
Azitra Inc |
10%+ Owner |
Series A-1 Convertible Preferred Stock |
0 |
|
|
Jun 21, 2023 |
Directly held by Bios Fund II QP, LP |
Azitra Inc |
10%+ Owner |
Series A Convertible Preferred Stock |
0 |
|
|
Jun 21, 2023 |
Directly held by Bios Fund I, LP |
Azitra Inc |
10%+ Owner |
Series A Convertible Preferred Stock |
0 |
|
|
Jun 21, 2023 |
Directly held by Bios Fund I QP, LP |
Azitra Inc |
10%+ Owner |
Series B Convertible Preferred Stock |
0 |
|
|
Jun 21, 2023 |
Directly held by Bios Fund III, LP |
Azitra Inc |
10%+ Owner |
Series B Convertible Preferred Stock |
0 |
|
|
Jun 21, 2023 |
Directly held by Bios Fund III NT, LP |
Azitra Inc |
10%+ Owner |
Series B Convertible Preferred Stock |
0 |
|
|
Jun 21, 2023 |
Directly held by Bios Fund III QP, LP |
Azitra Inc |
10%+ Owner |
Series B Convertible Preferred Stock |
0 |
|
|
Jun 21, 2023 |
Directly held by Bios Fund II, LP |
Azitra Inc |
10%+ Owner |
Series B Convertible Preferred Stock |
0 |
|
|
Jun 21, 2023 |
Directly held by Bios Fund II NT, LP |
Azitra Inc |
10%+ Owner |
Series B Convertible Preferred Stock |
0 |
|
|
Jun 21, 2023 |
Directly held by Bios Fund II QP, LP |
Lantern Pharma Inc. |
10%+ Owner |
Series A Warrants |
0 |
|
|
Jan 17, 2024 |
By Bios Fund II, LP |
Lantern Pharma Inc. |
10%+ Owner |
Series A Warrants |
0 |
|
|
Jan 17, 2024 |
By Bios Fund II NT, LP |
Lantern Pharma Inc. |
10%+ Owner |
Series A Warrants |
0 |
|
|
Jan 17, 2024 |
By Bios Fund II QP, LP |